Veit-Haibach P - Search Results

1

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.

Wong D, Luo P, Oldfield LE, Gong H, Brunga L, Rabinowicz R, Subasri V, Chan C, Downs T, Farncombe KM, Luu B, Norman M, Sobotka JA, Uju P, Eagles J, Pedersen S, Wellum J, Danesh A, Prokopec SD, Stutheit-Zhao EY, Znassi N, Heisler LE, Jovelin R, Lam B, Lujan Toro BE, Marsh K, Sundaravadanam Y, Torti D, Man C, Goldenberg A, Xu W, Veit-Haibach P, Doria AS, Malkin D, Kim RH, Pugh TJ. Wong D, et al. Among authors: veit haibach p. Cancer Discov. 2024 Jan 12;14(1):104-119. doi: 10.1158/2159-8290.CD-23-0456. Cancer Discov. 2024. PMID: 37874259 Free PMC article.

2

¹⁸ F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies.

Wong ET, Dmytriw AA, Yu E, Waldron J, Lu L, Fazelzad R, de Almeida JR, Veit-Haibach P, O'Sullivan B, Xu W, Huang SH. Wong ET, et al. Head Neck. 2019 Feb;41(2):551-561. doi: 10.1002/hed.25513. Epub 2018 Nov 20. Head Neck. 2019. PMID: 30456825

3

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.

Ma LX, Taylor K, Espin-Garcia O, Anconina R, Suzuki C, Allen MJ, Honorio M, Bach Y, Allison F, Chen EX, Brar S, Swallow CJ, Yeung J, Darling GE, Wong R, Kalimuthu SN, Jang RW, Veit-Haibach P, Elimova E. Ma LX, et al. Cancer Med. 2021 Jan;10(1):199-207. doi: 10.1002/cam4.3604. Epub 2020 Dec 9. Cancer Med. 2021. PMID: 33295697 Free PMC article.

4

Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.

Kohan A, Hinzpeter R, Kulanthaivelu R, Mirshahvalad SA, Avery L, Tsao M, Li Q, Ortega C, Metser U, Hope A, Veit-Haibach P. Kohan A, et al. Among authors: veit haibach p. Acad Radiol. 2024 Feb 20:S1076-6332(24)00053-9. doi: 10.1016/j.acra.2024.01.031. Online ahead of print. Acad Radiol. 2024. PMID: 38383258 Free article.

5

Detection of clinically significant prostate cancer with ¹⁸F-DCFPyL PET/multiparametric MR.

Metser U, Ortega C, Perlis N, Lechtman E, Berlin A, Anconina R, Eshet Y, Chan R, Veit-Haibach P, van der Kwast TH, Liu A, Ghai S. Metser U, et al. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3702-3711. doi: 10.1007/s00259-021-05355-7. Epub 2021 Apr 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33846845

6

Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer.

Anconina R, Ortega C, Metser U, Liu ZA, Elimova E, Allen M, Darling GE, Wong R, Taylor K, Yeung J, Chen EX, Swallow CJ, Jang RW, Veit-Haibach P. Anconina R, et al. Clin Nucl Med. 2022 Aug 1;47(8):684-691. doi: 10.1097/RLU.0000000000004253. Epub 2022 May 11. Clin Nucl Med. 2022. PMID: 35543637

7

Influence of sarcopenia, clinical data, and 2-[¹⁸F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer.

Anconina R, Ortega C, Metser U, Liu ZA, Suzuki C, McInnis M, Darling GE, Wong R, Taylor K, Yeung J, Chen EX, Swallow CJ, Bajwa J, Jang RW, Elimova E, Veit-Haibach P. Anconina R, et al. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1012-1020. doi: 10.1007/s00259-021-05514-w. Epub 2021 Sep 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 34491404

8

Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About.

Ma LX, Panov ED, Allen MJ, Darling GE, Yeung JC, Swallow CJ, Brar SS, Wong RK, Veit-Haibach P, Kalimuthu SN, Chen EX, Jang RW, Elimova E. Ma LX, et al. J Natl Compr Canc Netw. 2022 Feb;20(2):193-202. doi: 10.6004/jnccn.2021.7118. J Natl Compr Canc Netw. 2022. PMID: 35130503 Review.

9

Impact of ¹⁸F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer.

Basso Dias A, Finelli A, Bauman G, Veit-Haibach P, Berlin A, Ortega C, Avery L, Metser U. Basso Dias A, et al. Radiology. 2022 Sep;304(3):600-608. doi: 10.1148/radiol.211836. Epub 2022 May 24. Radiology. 2022. PMID: 35608445

10

Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies.

Basso Dias A, Ghai S, Ortega C, Mirshahvalad SA, Perlis N, Berlin A, Avery L, Veit-Haibach P, van der Kwast T, Metser U. Basso Dias A, et al. Clin Nucl Med. 2023 Oct 1;48(10):e462-e467. doi: 10.1097/RLU.0000000000004819. Clin Nucl Med. 2023. PMID: 37682613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page